Apellis Pharmaceuticals, Inc. (APLS) Tops Q4 EPS by 1c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q4 EPS of ($1.50), $0.01 better than the analyst estimate of ($1.51). Revenue for the quarter came in at $22.7 million versus the consensus estimate of $24.26 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Lennar Corp. (LEN) Misses Q2 EPS by 1c
• Medtronic completes $550 million Scientia Vascular acquisition